ACADIA operates two core franchises: its neuroscience franchise anchored by NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis, and its neuro-rare disease franchise anchored by DAYBUE (trofinetide) for Rett syndrome. The company is advancing its R&D pipeline with plans to initiate five Phase 2 or Phase 3 studies across eight disclosed programs and deliver four Phase 2 or Phase 3 readouts by the end of 2027.
Cyborg Score Rationale
ACADIA demonstrates solid commercial momentum with two established revenue-generating products and a robust pipeline spanning neuropsychiatric and rare disease markets. Growth trajectory toward $1.7B in 2028 revenues, strong clinical development pace, and market leadership in specialized neurological indications provide competitive advantages, though reliance on limited product portfolio and regulatory execution risks warrant monitoring.
Top Insights
DAYBUE STIX, launched in Q1 2026, represents an exciting opportunity to deliver more flexible patient options and strengthen leadership in Rett syndrome care.
Remlifanserin is expected to account for approximately $4 billion of the $11 billion peak sales opportunity across its current pipeline, with potential in both Alzheimer's disease psychosis and Lewy body dementia psychosis.
Phase 3 study results in Japan for trofinetide in Rett syndrome treatment are anticipated between October 2026 and March 2027, supporting international expansion.
Phase 2 RADIANT study results for remlifanserin in Alzheimer's disease psychosis are expected between August and October 2026.
Named Competitors
Parkinson's disease psychosis treatments — Competing medications for psychosis in neurological disorders
Rett syndrome therapeutics — Competing treatments in rare genetic neurological disorders
Alzheimer's disease treatments — Broader competition in Alzheimer's disease and related dementias
Recent Developments
(January 2026) DAYBUE STIX U.S. launch begins Q1 2026 on limited basis with full launch planned Q2 2026
(January 2026) CEO announced 2026 as a pivotal year for sustained growth and pipeline advancement
(2025) FDA approved DAYBUE STIX (trofinetide) for oral solution as new powder formulation for Rett syndrome treatment
Open the full interactive ACADIA Pharmaceuticals Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.